Heartflow (NASDAQ:HTFL) Director Sells $228,050.00 in Stock

Heartflow, Inc. (NASDAQ:HTFL) Director Julie Cullivan sold 9,122 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $25.00, for a total transaction of $228,050.00. Following the transaction, the director owned 27,291 shares in the company, valued at approximately $682,275. The trade was a 25.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Heartflow Trading Down 7.6%

Shares of HTFL opened at $22.98 on Monday. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22. The firm’s 50 day moving average is $28.43 and its 200-day moving average is $30.97. The stock has a market capitalization of $1.96 billion and a PE ratio of -12.70.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Stifel Nicolaus increased their target price on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Canaccord Genuity Group raised their price target on Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wells Fargo & Company assumed coverage on shares of Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Institutional Investors Weigh In On Heartflow

A number of institutional investors have recently added to or reduced their stakes in the business. XXEC Inc. increased its position in Heartflow by 40.5% in the 4th quarter. XXEC Inc. now owns 41,920 shares of the company’s stock valued at $1,222,000 after acquiring an additional 12,088 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Heartflow during the fourth quarter worth $72,000. Invesco Ltd. lifted its holdings in shares of Heartflow by 463.9% during the fourth quarter. Invesco Ltd. now owns 577,397 shares of the company’s stock worth $16,831,000 after purchasing an additional 475,004 shares during the period. XTX Topco Ltd grew its stake in shares of Heartflow by 282.6% in the fourth quarter. XTX Topco Ltd now owns 43,205 shares of the company’s stock worth $1,259,000 after purchasing an additional 31,913 shares during the last quarter. Finally, VARCOV Co. acquired a new stake in Heartflow in the fourth quarter valued at $1,657,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.